Type A natriuretic peptides exhibit different bronchoprotective effects in rats

Eur J Pharmacol. 1994 Dec 27;271(2-3):395-402. doi: 10.1016/0014-2999(94)90799-4.

Abstract

The protective effect of 11.4, 22.8 or 45.6 pmol/kg/min cardiodilatin/atrial natriuretic peptide (CDD/ANP-(99-126)), urodilatin (CDD/ANP-(95-126)) or vehicle intravenously against acetylcholine-induced bronchoconstriction was compared in spontaneously breathing, halothane-anesthetized Wistar rats. The inhalation of acetylcholine induced significant alterations of the spontaneous breathing parameters evaluated by whole-body plethysmography without significant differences between the treatment groups. Forced parameters detect airflow changes with a greater sensitivity and were measured in hyperventilation-induced temporary apnoea after the challenge. The forced expiratory volume in 0.1 s revealed a significant protective effect of 11.4 pmol/kg/min urodilatin compared to the controls whereas the parameters of the forced expiratory flow-volume curve were significantly preserved by 11.4 and 22.8 pmol/kg/min urodilatin (P < 0.05). Urodilatin showed protective effects against an acetylcholine challenge whereas CDD/ANP-(99-126) was without significant influence.

MeSH terms

  • Acetylcholine / pharmacology
  • Animals
  • Atrial Natriuretic Factor / pharmacology*
  • Bronchi / drug effects*
  • Bronchi / physiology
  • Female
  • Heart Rate / drug effects
  • Muscle Proteins / pharmacology*
  • Peptide Fragments / pharmacology*
  • Rats
  • Rats, Wistar

Substances

  • Muscle Proteins
  • Peptide Fragments
  • Ularitide
  • Atrial Natriuretic Factor
  • cardiodilatin
  • Acetylcholine